Industry analysts say Genetics Institute's fortunes depend ondevelopment of its product portfolio. Here are highlights of theGI pipeline:
Products under FDA review:
-- Recombinate Factor VIII: Blood clotting protein to treathemophilia. Filed May 1990. Licensed to Baxter HealthcareCorp. GI and Baxter have cross-licensed GI's patent withGenentech Inc. and its partner, Cutter Labs.
-- Leucomax GM-CSF (granulocyte macrophage colonystimulating factor): Protein to increase white blood cells to treatside effects of chemotherapy and to aid in bone marrowtransplants. Filed February 1990. Licensed to Sandoz Ltd.,which will market it with Schering-Plough Corp.
Products in clinical trials:
-- Macrophage colony stimulating factor (M-CSF): Increasestumor-cell killing ability of white blood cells. Phase I/II forcancers and infectious diseases. GI is developing on its own.
-- Interleukin-3 (IL-3): Stimulates immune system. Phase I/IItrials by licensee, Sandoz, for cancer and blood cell disorders.
-- 3F8 monoclonal antibody in Phase I/II trials alone and withM-CSF to treat neuroblastoma, melanoma and small-cell lungcancer. GI licensed 3F8 from Memorial Sloan Kettering.
Products in pre-clinical trials:
-- Bone morphogenic protein-2 (BMP-2): Advanced pre-clinicals for treating bone damage. GI is developing BMP jointlywith Yamanouchi Pharmaceutical Co.
(c) 1997 American Health Consultants. All rights reserved.